JP2010514684A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010514684A5 JP2010514684A5 JP2009543168A JP2009543168A JP2010514684A5 JP 2010514684 A5 JP2010514684 A5 JP 2010514684A5 JP 2009543168 A JP2009543168 A JP 2009543168A JP 2009543168 A JP2009543168 A JP 2009543168A JP 2010514684 A5 JP2010514684 A5 JP 2010514684A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- aryl
- haloalkyl
- heterocycloalkyl
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims 26
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 20
- 125000003118 aryl group Chemical group 0.000 claims 19
- 125000001072 heteroaryl group Chemical group 0.000 claims 18
- 125000000753 cycloalkyl group Chemical group 0.000 claims 17
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 16
- 125000003710 aryl alkyl group Chemical group 0.000 claims 15
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 12
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 claims 12
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 10
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 8
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 8
- 208000024891 symptom Diseases 0.000 claims 7
- 150000001875 compounds Chemical class 0.000 claims 6
- 125000001188 haloalkyl group Chemical group 0.000 claims 6
- 125000005843 halogen group Chemical group 0.000 claims 6
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims 6
- 208000019901 Anxiety disease Diseases 0.000 claims 4
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 125000000304 alkynyl group Chemical group 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 239000003446 ligand Substances 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 4
- 206010012289 Dementia Diseases 0.000 claims 3
- 208000019022 Mood disease Diseases 0.000 claims 3
- 208000020114 Schizophrenia and other psychotic disease Diseases 0.000 claims 3
- 239000000556 agonist Substances 0.000 claims 3
- 208000010877 cognitive disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims 3
- 208000019116 sleep disease Diseases 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 230000001430 anti-depressive effect Effects 0.000 claims 2
- 230000000561 anti-psychotic effect Effects 0.000 claims 2
- 239000000935 antidepressant agent Substances 0.000 claims 2
- 229940005513 antidepressants Drugs 0.000 claims 2
- 125000004965 chloroalkyl group Chemical group 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims 1
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 102100031172 C-C chemokine receptor type 1 Human genes 0.000 claims 1
- 101710149814 C-C chemokine receptor type 1 Proteins 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 108010065028 Metabotropic Glutamate 5 Receptor Proteins 0.000 claims 1
- 102100036837 Metabotropic glutamate receptor 2 Human genes 0.000 claims 1
- 102100038357 Metabotropic glutamate receptor 5 Human genes 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 108010040718 Neurokinin-1 Receptors Proteins 0.000 claims 1
- 208000001294 Nociceptive Pain Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 102100037346 Substance-P receptor Human genes 0.000 claims 1
- 206010046543 Urinary incontinence Diseases 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 230000001773 anti-convulsant effect Effects 0.000 claims 1
- 239000001961 anticonvulsive agent Substances 0.000 claims 1
- 229960003965 antiepileptics Drugs 0.000 claims 1
- -1 antipsychotic Substances 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 239000002249 anxiolytic agent Substances 0.000 claims 1
- 230000000949 anxiolytic effect Effects 0.000 claims 1
- 239000003693 atypical antipsychotic agent Substances 0.000 claims 1
- 229940127236 atypical antipsychotics Drugs 0.000 claims 1
- 229940049706 benzodiazepine Drugs 0.000 claims 1
- 239000000841 delta opiate receptor agonist Substances 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002996 emotional effect Effects 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 206010022437 insomnia Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 108010038421 metabotropic glutamate receptor 2 Proteins 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 230000036651 mood Effects 0.000 claims 1
- 239000004050 mood stabilizer Substances 0.000 claims 1
- 229940127237 mood stabilizer Drugs 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 229960002715 nicotine Drugs 0.000 claims 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims 1
- 125000005010 perfluoroalkyl group Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000002464 receptor antagonist Substances 0.000 claims 1
- 229940044551 receptor antagonist Drugs 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 229940126570 serotonin reuptake inhibitor Drugs 0.000 claims 1
- 239000003772 serotonin uptake inhibitor Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87098206P | 2006-12-20 | 2006-12-20 | |
| PCT/US2007/088055 WO2008079848A1 (en) | 2006-12-20 | 2007-12-19 | Compounds and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010514684A JP2010514684A (ja) | 2010-05-06 |
| JP2010514684A5 true JP2010514684A5 (enExample) | 2010-12-16 |
Family
ID=39562913
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009543168A Pending JP2010514684A (ja) | 2006-12-20 | 2007-12-19 | 化合物及びその使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20100056492A1 (enExample) |
| EP (1) | EP2120957A4 (enExample) |
| JP (1) | JP2010514684A (enExample) |
| CN (1) | CN101610773A (enExample) |
| WO (1) | WO2008079848A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0565257A (ja) * | 1991-07-05 | 1993-03-19 | Hokuriku Seiyaku Co Ltd | 多環式化合物及びその用途 |
| US6239134B1 (en) * | 1999-03-03 | 2001-05-29 | American Home Products Corp. | Diazole derivatives as serotonergic agents |
| BR0317528A (pt) * | 2002-12-20 | 2005-11-22 | Basf Ag | Uso dos compostos, métodos para o controle de insetos, aracnìdeos ou nematodos, e para a proteção de plantas em crescimento contra o ataque ou a infestação por insetos, aracnìdeos ou nematodos, compostos, e, composições |
| US20060217366A1 (en) * | 2003-07-02 | 2006-09-28 | Astrazeneca Ab | Method of treating schizophrenia and other disorders |
| DE602004028739D1 (de) * | 2003-07-02 | 2010-09-30 | Astrazeneca Ab | Metabolit von quetiapine |
| PL1696931T3 (pl) * | 2003-12-22 | 2009-10-30 | Acadia Pharm Inc | Aminopodstawione analogi diarylo[A,D]cykloheptenowe jako agoniści receptorów muskarynowych i sposoby leczenia chorób neuropsychiatrycznych |
| US20050171088A1 (en) * | 2004-01-30 | 2005-08-04 | Astrazeneca Ab | Treatment of psychoses with dibenzothiazepine antipsychotic |
-
2007
- 2007-12-19 WO PCT/US2007/088055 patent/WO2008079848A1/en not_active Ceased
- 2007-12-19 EP EP07865847A patent/EP2120957A4/en not_active Withdrawn
- 2007-12-19 JP JP2009543168A patent/JP2010514684A/ja active Pending
- 2007-12-19 US US12/520,167 patent/US20100056492A1/en not_active Abandoned
- 2007-12-19 CN CNA2007800515097A patent/CN101610773A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5337054B2 (ja) | ムスカリン受容体アンタゴニストとベータ−２−アドレナリン受容体アゴニストの組み合わせ | |
| CN1060775C (zh) | 用作神经递质重摄取抑制剂的稠合莨菪烷衍生物 | |
| CN115154470B (zh) | 使用食欲素-2受体拮抗剂治疗抑郁症的方法 | |
| EA036446B1 (ru) | Соединения и композиции для подавления активности shp2 | |
| JP2008513498A5 (enExample) | ||
| JP2010531292A5 (ja) | １１−ピペラジン−１−イルジベンゾ[ｂ,ｆ][１,４]チアゼピンの誘導体及びその使用 | |
| RU2012141706A (ru) | Производные оксадиазола и их применение в качестве потенцирующих средств в отношении метаботропных глутаматных рецепторов-842 | |
| TWI568733B (zh) | 新穎的唏及１，１ａ，２，７ｂ－四氫環丙烷［ｃ］唏吡啶并吡化合物 | |
| CN1893948A (zh) | 蕈毒碱性乙酰胆碱受体拮抗剂 | |
| JP2010514682A5 (enExample) | ||
| JP2016507581A (ja) | Ｃｎｓおよび他の障害を治療するための、ｐｄｅ４アイソザイムの阻害薬としてのアザベンゾイミダゾール化合物 | |
| JP2007532546A5 (enExample) | ||
| JP2012512165A (ja) | 四環系ピラジノインドールを用いた多発性硬化症の治療方法 | |
| JP2004504376A (ja) | 医薬製剤としてのセロトニンアゴニスト（５ｈｔ２）とアンタゴニスト（５ｈｔ６）の新規組み合わせ | |
| TW201831460A (zh) | 雜芳基苯氧基苯甲醯胺kappa類鴉片配體 | |
| JP2010535858A5 (enExample) | ||
| JP2005508969A5 (enExample) | ||
| JP2016531880A (ja) | ガンマセクレターゼモジュレーターとしての新規二環式ピリジノン | |
| JP2010514683A5 (enExample) | ||
| JP2008543782A (ja) | ５−ｈｔ１ａ受容体のピペラジン−ピペリジンアンタゴニストおよびアゴニスト | |
| KR20180101568A (ko) | 6,7-디히드로-5H-피라졸로[5,1-b][1,3]옥사진-2-카르복스아미드 화합물 | |
| CN112313230B (zh) | 用于治疗、缓解或预防与Tau聚集体相关的病症的新型化合物 | |
| CN102088976B (zh) | 包含毒蕈碱性受体拮抗剂和β2-肾上腺素受体激动剂的药物产品 | |
| JPWO2017119456A1 (ja) | せん妄の予防または治療剤 | |
| JP2010514684A5 (enExample) |